Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
Amgen announces positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Amgen announced positive topline phase 3 results for dazodalibep in moderate-to-severe systemic Sjogren's disease. The late-stage trial success of the Horizon-acquired fusion protein prompted higher share prices and discussions regarding the company's investment case.
Epilogue added 52d ago, after coverage quieted.
The brief
Recent coverage from outlets including Reuters, Fierce Biotech, Endpoints News, Yahoo, FirstWord, Kalkine Media, GuruFocus, Investor's Business Daily, and PR Newswire details a significant clinical development for Amgen. The company announced positive topline Phase 3 results for its autoimmune drug, a fusion protein acquired through Horizon. Specifically, the late-stage trial evaluated dazodalibep for patients suffering from moderate-to-severe systemic Sjögren's disease. According to the reporting, the therapy successfully eased the severity of the condition in this initial Phase 3 trial, marking a major milestone for the therapeutic candidate. Financial and industry publications extensively covered the market and business implications of the clinical trial success.
Investor's Business Daily noted that shares bounced higher following the announcement, while GuruFocus and Kalkine Media discussed shifts in the investment case and valuation for AMGN on NASDAQ following a 4.3 percent rally. Fierce Biotech and FirstWord both emphasized that the successful fusion protein originated from the Horizon acquisition, highlighting the strategic value of that corporate transaction for Amgen's pipeline. The background established by the coverage centers on the clinical evaluation of dazodalibep as a treatment for systemic Sjögren's disease, an autoimmune condition characterized by moderate-to-severe systemic involvement. The asset came into Amgen's portfolio via the Horizon acquisition, making this late-stage trial success a critical test for the acquired pipeline. Prior to this announcement, market watchers and investors were closely monitoring the changing investment case for AMGN, as reflected in analyses from financial platforms discussing the stock valuation after the recent equity rally.
As coverage of the trial concludes initial reporting, future updates will depend on further disclosures from Amgen regarding subsequent trial phases, regulatory filings, and detailed data presentations. Current reports do not yet specify timelines for upcoming regulatory submissions or the exact schedule for presenting comprehensive trial datasets at upcoming medical congresses. Observers and market analysts will continue tracking how this late-stage success influences the broader valuation and performance of AMGN shares on NASDAQ.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (93% supported) Updated 53d ago.
Quick answers
What drug achieved success in the Phase 3 trial?
Dazodalibep, a fusion protein acquired from Horizon, achieved success in the late-stage trial.
Which outlets reported on the trial results?
Coverage came from Reuters, Fierce Biotech, Endpoints News, Yahoo, FirstWord, Kalkine Media, GuruFocus, Investor's Business Daily, and PR Newswire.
What condition does the drug treat?
The drug targets moderate-to-severe systemic Sjögren's disease.
Coverage (10)
- First of Amgen’s Phase III Sjögren’s disease trials succeeds Yahoo · 56d ago
- Amgen's Horizon-sourced fusion protein succeeds in late-stage Sjögren's study FirstWord · 56d ago
- What is changing in the investment case for Amgen (NASDAQ:AMGN)? Kalkine Media · 56d ago
- Is Amgen Inc (AMGN) Overvalued After 4.3% Rally? GF Value Says O GuruFocus · 56d ago
- AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE Amgen · 56d ago
- Amgen Boasts Success In Sjogren's; Shares Bound Higher Investor's Business Daily · 56d ago
- AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE PR Newswire · 56d ago
- Amgen’s Phase 3 Sjögren’s win; Novartis’ $900M radioligand deal Endpoints News · 56d ago
- Amgen's autoimmune drug succeeds in late-stage trial Reuters · 56d ago
- Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win Fierce Biotech · 56d ago
Topics
Related trends
Biotech Tops The 'Most Bullish Conversations' And Breaks Out
Biotech markets surge in bullish conversations amid major trial outcomes and regulatory updates from key industry players.
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease therapies.
Meta Reportedly Rebranding Horizon+ to 'Meta VR+', Adding Popular 3D Films to Game Service
Meta is reportedly rebranding Horizon+ to Meta VR+ while integrating popular 3D films into its game service.
Beyond statins, one drug lowered heart attack risk by 20%
Amgen's Repatha demonstrates a lower risk of heart attacks compared to ezetimibe in a large real-world study.
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Moderna raises its 2026 outlook and swings to a profit as newer vaccines and cancer treatments gain traction.
Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.